Business Description
Founded in 2013 and headquartered in Luxembourg, Alvotech develops and manufactures biosimilar medicines designed to offer more accessible alternatives to established biologic treatments. The company's portfolio spans a wide range of conditions, including inflammatory diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis, as well as eye conditions, bone-related complications from cancer, allergic asthma, and certain cancers. Its products are built to closely replicate some of the world's best-known biologic drugs, including Humira, Stelara, Eylea, and Keytruda, among others. Alvotech serves patients across global markets through its growing pipeline of approved and in-development biosimilar treatments.
